• Vaccine Name: E. histolytica SREHP protein vaccine
• Target Pathogen: Entamoeba histolytica
• Target Disease: Amoebiasis
• Vaccine Ontology ID: VO_0011416
• Type: Subunit vaccine
• Status: Research
• Antigen: E. histolytica serine-rich protein (SREHP)
• SREHP gene engineering:
  • Type: Recombinant protein preparation
  • Description: Expressed the SREHP-MBP molecule in an attenuated vaccine strain of Salmonella typhimurium (Zhang and Stanley, 1996).
  • Detailed Gene Information: Click Here.
• Immunization Route: Oral

Gerbil Response

• Vaccination Protocol: female BALB/c mice or gerbils were deprived of water and food for 4 h and then were given 50 ml of 10% sodium bicarbonate solution per orogastric gavage with a 21-gauge ball-tipped gavage needle. Five minutes later, they received by gavage 50 ml of 0.16Mphosphate-buffered saline (PBS), pH 7.0, containing 109 S. typhimurium cells harboring either pSS3137 (Stm-SREHP) or pYA3137 (Stm-Ctrl). Mice and gerbils were immunized on days 0, 7, and 21. Serum samples were obtained on days 0, 7, 21, and 28 (Zhang and Stanley, 1996).
• Challenge Protocol: On day 35 (14 days following the final booster immunization) control gerbils vaccinated with Stm-Ctrl and gerbils vaccinated with Stm-SREHP were challenged intrahepatically with 5 x 10^5 E. histolytica HM1:IMSS trophozoites (Zhang and Stanley, 1996).
• Efficacy: Report describes a recombinant fusion protein containing the serine-rich Entamoeba histolytica protein (SREHP), a protective antigen derived from virulent amebae, and a bacterially derived maltose-binding protein (MBP) from an attenuated strain of Salmonella typhimurium. Gerbils vaccinated with S typhimurium SREHP-MBP were protected against amebic liver abscess after challenge with E. histolytica, the most common extraintestinal complication of amebiasis (Zhang and Stanley, 1996).